UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

April 2019

 

Commission file number: 001-36288

 

Akari Therapeutics, Plc

(Translation of registrant's name into English)

 

75/76 Wimpole Street

London W1G 9RT

United Kingdom

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F   x        Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

 

 

 

 

 
 

 

CONTENTS

 

Further to a Form 6-K of Akari Therapeutics Plc dated April 26, 2019, on April 28, 2019, a poster presentation was made at the Association for Research in Vision and Ophthalmology annual meeting in Vancouver titled “Targeting the leukotriene B4 pathway and/or complement C5 via dual-functional recombinant coversin (nomacopan) in Experimental Autoimmune Uveitis (EAU)”. A copy of the poster is attached hereto as Exhibit 99.1.

  

Exhibit No.

 

99.1

 

Poster titled “Targeting the leukotriene B4 pathway and/or complement C5 via dual-functional recombinant coversin (nomacopan) in Experimental Autoimmune Uveitis (EAU)”.  

 

 

 

 

  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Akari Therapeutics, Plc  
  (Registrant)  
       
  By: /s/ Clive Richardson  
  Name:   Clive Richardson  
  Interim Chief Executive Officer and Chief Operating Officer  

       

Date: April 29, 2019

 

 

 

 

 

 

 

Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Akari Therapeutics Charts.
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Akari Therapeutics Charts.